|
Status |
Public on Apr 24, 2024 |
Title |
Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3 [ChIP-seq] |
Organism |
Mus musculus |
Experiment type |
Genome binding/occupancy profiling by high throughput sequencing
|
Summary |
Histone lysine methyltransferases KMT2C and KMT2D are among the most commonly mutated genes in the highly metastatic TNBC subtype of breast cancer. However, it is not known if mutations of either of these genes similarly effect epigenomic and transcriptomic landscape or if a specific downstream target might influence metastases. Here, we generated heterogenous Kmt2c or Kmt2d KO murine TNBC cell lines side-by-side and performed in vivo metastases assay in syngeneic immunocompetent mice. Deficiency for either Kmt2c or Kmt2d, both, induced brain metastases from formerly non-metastatic cells. scRNAseq showed activation of pro-inflammatory pathways but conversely also increase of immune checkpoint blocking genes. Interestingly, histone mass spectrometry revealed changes of H3K27 but not the main substrate H3K4. However, ChIPseq for both, H3K4 and H3K27 modifications showed significant changes compared to wildtype cells. Strikingly, genome occupancy of H3K27me3 was reduced while H3K27 demethylase KDM6A was enriched on genomes of KO cells. Integration with gene expression data revealed significant correlations with histone and KDM6A ChIPseq, identifying them as a main driver of Kmt2c or Kmt2d KO-specific gene regulation. Although our datasets revealed more unique than shared signatures, we found Mmp3 being a common target upon Kmt2c or Kmt2d KO. Indeed, downregulation of Mmp3 reversed induction of Kmt2c and Kmt2d KO-dependent brain metastases. Finally, we found that Kdm6a knockdown reduces Mmp3 levels, again, leading to reduction of brain metastases of Kmt2c or Kmt2d KO cells.
|
|
|
Overall design |
We generated either Kmt2c or Kmt2d KO derivatives of the 168FARN an 67NR cell line using CRISPR/Cas9
|
Web link |
https://pubmed.ncbi.nlm.nih.gov/38926506/
|
|
|
Contributor(s) |
Seehawer M, Zheqi L, Nishida J, Foidart P, Reiter A, Rojas E, Goyette M, Cejas P, Goldman S, Adelman K, Long H, Papanastasiou M, Polyak K |
Citation(s) |
38926506 |
NIH grant(s) |
Grant ID |
Grant title |
Affiliation |
Name |
P01 CA250959 |
New therapeutic vulnerabilities in breast cancer |
DANA-FARBER CANCER INSTITUTE |
Kornelia Polyak |
R35 CA197623 |
Targeting intratumor heterogeneity in breast cancer |
DANA-FARBER CANCER INSTITUTE |
Kornelia Polyak |
|
|
Submission date |
Jul 14, 2023 |
Last update date |
Jul 24, 2024 |
Contact name |
Kornelia Polyak |
E-mail(s) |
kornelia_polyak@dfci.harvard.edu
|
Phone |
617-632-2106
|
Organization name |
Dana-Farber Cancer Institute
|
Department |
Medical Oncology
|
Lab |
Polyak
|
Street address |
450 Brookline Ave
|
City |
Boston |
State/province |
MA |
ZIP/Postal code |
02215 |
Country |
USA |
|
|
Platforms (1) |
GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
Samples (54)
|
|
This SubSeries is part of SuperSeries: |
GSE237392 |
Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3 |
|
Relations |
BioProject |
PRJNA994871 |